These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8334645)

  • 41. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.
    Koh KN; Im HJ; Kim H; Kang HJ; Park KD; Shin HY; Ahn HS; Lee JW; Yoo KH; Sung KW; Koo HH; Lim YT; Park JE; Park BK; Park HJ; Seo JJ
    J Korean Med Sci; 2017 Apr; 32(4):642-649. PubMed ID: 28244291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
    Giles FJ; Cortes JE; Thomas DA; Garcia-Manero G; Faderl S; Jeha S; De Jager RL; Kantarjian HM
    Clin Cancer Res; 2002 Jul; 8(7):2134-41. PubMed ID: 12114413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicin.
    Trucco M; Barredo JC; Goldberg J; Leclerc GM; Hale GA; Gill J; Setty B; Smith T; Lush R; Lee JK; Reed DR
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27224. PubMed ID: 29856514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
    Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
    J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
    O'Brien MM; Lacayo NJ; Lum BL; Kshirsagar S; Buck S; Ravindranath Y; Bernstein M; Weinstein H; Chang MN; Arceci RJ; Sikic BI; Dahl GV
    Pediatr Blood Cancer; 2010 May; 54(5):694-702. PubMed ID: 20209646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia.
    Kritz AD; Raptis G; Menendez-Botet C; Maslak P; Jakubowski A
    Am J Hematol; 1996 Feb; 51(2):117-21. PubMed ID: 8579051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
    Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
    Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
    Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer.
    Olver IN; Stephenson J; Schulze D
    Cancer Chemother Pharmacol; 2000; 46(4):338-41. PubMed ID: 11052632
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study.
    Smit EF; Willemse PH; Sleijfer DT; Uges DR; Postmus PE; Meijer S; Terheggen PM; Mulder NH; de Vries EG
    J Clin Oncol; 1991 Jan; 9(1):100-10. PubMed ID: 1985158
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
    Kantarjian HM; Gandhi V; Kozuch P; Faderl S; Giles F; Cortes J; O'Brien S; Ibrahim N; Khuri F; Du M; Rios MB; Jeha S; McLaughlin P; Plunkett W; Keating M
    J Clin Oncol; 2003 Mar; 21(6):1167-73. PubMed ID: 12637486
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report.
    Franklin JL; Seibel NL; Krailo M; Fu C; Adamson PC; Reaman G;
    Pediatr Blood Cancer; 2008 Mar; 50(3):533-6. PubMed ID: 17668867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
    Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
    Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
    Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
    Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
    Nichols CR; Tricot G; Williams SD; van Besien K; Loehrer PJ; Roth BJ; Akard L; Hoffman R; Goulet R; Wolff SN
    J Clin Oncol; 1989 Jul; 7(7):932-9. PubMed ID: 2544687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
    Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.